Venture Capital Access Online | The eMarketplace for the Venture Capital Industry

 

Home

Marketplace
Database
News
Store
Resources
Contact Us

 

 

News


VENTURE CAPITAL DIRECTORY | PRIVATE EQUITY DIRECTORY

List of Venture Capital / Private Equity Firms and Sources
Published since 1998, VCPro Database is the most reliable, up-to-date and affordable venture capital directory

2021 EDITION SPECIAL OFFER
Buy Now for only $119.95 plus a FREE 2022 update in January 2022

Learn More or Buy Now

VCPro Database 2021 24th Edition -- a downloadable and searchable venture capital database with 6,500+ venture capital and private equity firms worldwide. The most reliable, up-to-date and affordable venture capital directory of its kind. VCPro Database is available in both Windows and macOS versions. It has been published since 1998. (Updated JULY 2021)

Learn More » or Buy Now »




Encellin Closes $5.9M Seed Financing Co-Led by Khosla Ventures and SV Latam Capital

• Top-tier investor syndicate co-led by Khosla Ventures and SV Latam Capital (SVLC) with participation from Sandhill Angels and Y Combinator
• The financing will be used to expand the team and prepare its soft cell encapsulation device (CED) for clinical trials in hypoglycemia and hypocalcemia

SAN FRANCISCO, August 5, 2021-- Encellin, a personalized regenerative medicine biotech company developing novel cell-based approaches to deliver sustained therapies with a single implant, today announced the closing of a $5.9M Seed financing round. The round was co-led by Khosla Ventures and SV Latam Capital, with participation from Sandhill Angels and Y Combinator.

The new funding will be used to advance development of its technology platform and programs in hypoglycemia and hypocalcemia. The financing will also be used to build out the laboratory and also expand the team. Encellin will also expand into areas with readily available renewable cell sources and engineered cells, to encapsulate any cellular cargo in products from its proprietary platform.

Encellin builds implantable “cell pouches” to treat chronic diseases. The company’s technology combines ad novel cell encapsulation technology with functional cell therapies to treat chronic diseases, starting with endocrine disorders. Encellin’s lead programs focus on hypoglycemia, the highest unmet medical need in Type 1 diabetes and hypocalcemia, which affects one-third of dialysis patients. The platform is focused on leveraging the power of cells to deliver years of therapies with a single implant.

“This seed financing round led by leading investors, enables us to advance development of our Cell Encapsulation Device in a variety of different indications beginning with chronic endocrine disorders,” said Crystal Nyitray, Ph.D., CEO & Co-Founder, Encellin. “Our team converges the advanced technologies in nano-technology and bioengineering to develop our proprietary Encellin platform which utilizes known biocompatible materials fabricated into nanoporous, soft pouches to support cell function. We look forward to advancing our pipeline focused on endocrine disorders to leverage the power of cells to deliver sustained therapies for patients with a single implant.”

“Encellin’s encapsulation technology allows enclosed cells to function like smart molecular factories, releasing therapies when needed,” said Alex Morgan, M.D., Ph.D., Partner at Khosla Ventures. “The encapsulation technology protects the cells in the body, while enabling an incredible amount of flexibility for what kinds of cells are encapsulated and what their output can be. Today they are focusing on diabetes, but in the future a whole range of therapeutics might be secreted under regulatory control from engineered cells.”

About Encellin

Encellin is developing regenerative materials using cell transplant therapy. The company has developed cell transplant therapy for treating missing, damaged, or diseased cells and treatment of chronic diseases beginning with hypoglycemia and hypocalcemia. Its soft cell encapsulation device (CED) functions like a pouch to hold cells and help these cells survive in the body. Encellin’s CED allows enclosed cells to function like smart molecular factories, releasing therapeutics when needed. The founding team from the University of California San Francisco (UCSF) leads the way in nano-technology and bioengineering. The company is headquarted in San Francisco, CA. For more information, please visit www.encellin.com.

Contact:
Kimberly Ha
KKH Advisors
917-291-5744
kimberly.ha@kkhadvisors.com


News Index

Venture Capital Database 

 

 NEWS

Latest VC News
VC News Archive
News Search
RSS News Feed

List Your Firm

Entrepreneurs
Investors
Advisors

Venture Capital Database

VCPro Database
Download Trial
Buy Now

Business Plan Tools

Free Business Plan Template

 

Copyright © 1998-2021 Access InterComm  All rights reserved. 
Site Map | Privacy Statement | Legal Notice & Disclaimer